Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Calibration and Dose Equivalence Pharmacokinetic Study in Healthy Volunteers Comparing IkT-001Pro to Imatinib Mesylate 400mg

NCT05623774 is registered in ClinicalTrials.gov with Inhibikase Therapeutics as lead sponsor.

NCT NCT05623774
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05623774 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Calibration and Dose Equivalence Pharmacokinetic Study in Healthy Volunteers Comparing IkT-001Pro to Imatinib Mesylate 400mg
Lead sponsor
Inhibikase Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
December 16, 2022
Completion date
December 30, 2024
Enrollment
64 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cml